Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Part of paid clinical trials in Bakersfield, California.
- Sponsor
- Ocular Therapeutix, Inc.
- Study ID
- NCT07516132
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- OTX-TKI — DRUGIntravitreal Injection of OTX-TKI
Study Details
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Key Dates
- First listed
- Apr 7, 2026
- Start date
- Apr 27, 2026
- Status verified
- Jun 2026
- Primary completion
- Aug 1, 2030
- Completion
- Aug 1, 2030
Study Design
- Enrollment
- 850 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: OTX-TKI
Primary Outcome Measure
Incidence and severity of treatment-emergent adverse events (TEAEs) from Baseline (Day 1) through Week 144 [ Time Frame: from Baseline (Day 1) through Week 144 ]
Central Contacts
- Clinical Project Manager781-357-4000
- Nichole Wilkes770-375-1020
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| California Retina Consultants (CRC) | Bakersfield | California | 93309 | Dilsher Dhoot, MD (PRINCIPAL_INVESTIGATOR) |
| California Retina Consultants (CRC) | Santa Barbara | California | 93103 | |
| Retina Group of New England | Waterford | Connecticut | 06385 | Nauman A Chaudhry, MD (PRINCIPAL_INVESTIGATOR) |
| Retina Group of Florida - Fort Lauderdale | Fort Lauderdale | Florida | 33308 | Eduardo Uchiyama, MD (PRINCIPAL_INVESTIGATOR) |
| Cumberland Valley Retina Associates | Hagerstown | Maryland | 21740 | Allen Hu, MD (PRINCIPAL_INVESTIGATOR) |
| Mid Atlantic Retina Specialists | Hagerstown | Maryland | 21740 | Adam Gerstenblith, MD (PRINCIPAL_INVESTIGATOR) |
| Palmetto Retina Center | West Columbia | South Carolina | 29619 | Nitin Nigam, MD (PRINCIPAL_INVESTIGATOR) |
| Austin Retina Associates | Austin | Texas | 78705 | Robert William Wong, MD 512-451-0103 Robert William Wong, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Bakersfield, CA
By research site
California Retina Consultants (CRC)· Bakersfield, CACalifornia Retina Consultants (CRC)· Santa Barbara, CARetina Group of New England· Waterford, CTRetina Group of Florida - Fort Lauderdale· Fort Lauderdale, FLCumberland Valley Retina Associates· Hagerstown, MDMid Atlantic Retina Specialists· Hagerstown, MD
Related Studies
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular DegenerationPHASE3 · Not Yet Recruiting · Rophibio, Inc. · Phoenix, Arizona
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPHASE3 · Recruiting · 4D Molecular Therapeutics · Scottsdale, Arizona
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)PHASE3 · Recruiting · Adverum Biotechnologies, Inc. · Mesa, Arizona